Revamped Modus Switches To Sepsis, Septic Shock For Sevuparin

Swedish Biotech Had Unsuccessfully Targeted Sickle Cell Disease

 
• By Sten Stovall
  
Sepsis Indication
Modus plans IPO to fund sevuparin’s further clinical development
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D